Key Highlights
● The FDA issued warning letters to Neogen and contract manufacturer Sciarra Aeromed on Tuesday, September 29, 2026.
● The FDA said tests identified multiple fungal species in Neogen Vet HYCOAT, a product marketed as sterile.
● The product was linked to severe joint infections in nearly 100 horses and at least 20 deaths, FDA findings said.
● A response from Neogen to the FDA letters was not included in the reports that were reviewed.
Neogen Corporation (NASDAQ:NEOG) dropped on Tuesday, September 29, 2026, after the U.S. Food and Drug Administration issued warning letters to the company and its contract manufacturer, Sciarra Aeromed. The letters concern Neogen Vet HYCOAT, a veterinary product used in horses. Another market list also showed the stock among the day's decliners, with a similar reading on the size of the fall.
What the FDA Said
The FDA said tests identified multiple fungal species in Neogen Vet HYCOAT, a product marketed as sterile. According to an account of the FDA findings, the product was linked to severe joint infections in nearly 100 horses and at least 20 deaths. HYCOAT is a joint product used by veterinarians, and sterility is critical for anything injected into a joint, because contamination can cause serious infections. The letters went to both Neogen and Sciarra Aeromed, the contract manufacturer that produced the product. A response from Neogen was not included in the reports reviewed.
What a Warning Letter Means
An FDA warning letter is a formal notice that the agency believes a company has significant regulatory violations. It typically asks the company to respond and explain how it will correct the issues. Warning letters are not a fine or a court judgment, but investors take them seriously because they can lead to further regulatory action if problems are not resolved.
What Neogen Does
Neogen, based in Lansing, Michigan, develops and sells food-safety and animal-safety products. Its food-safety Business supplies test kits that help producers detect pathogens, allergens and other contaminants. Its animal-safety business sells veterinary instruments, biosecurity products, diagnostics and other supplies for livestock and companion animals, and that division is involved in Tuesday's news.
Health Care Under Pressure
Health care was among the declining sectors at midday. uniQure collapsed after four-year Huntington's disease data missed statistical significance, while Summit Therapeutics soared on a $2 billion Equity Investment from AstraZeneca.
Wall Street's Session
The S&P 500 closed at 7,670.84, down 12.85 points, and the Dow Jones Industrial Average closed at 51,349.92, down 131.59 points. The Nasdaq Composite ended little changed at 26,797.54. It was the fifth loss in six sessions for the three major indexes. Rising long-term Treasury yields were the main weight on the market, with the 30-year at its highest level since 2002 and the 10-year near a two-decade high.
Data and the Fed
The Conference Board's consumer confidence index fell to 81.9 in September from 88.6 in August, its lowest reading since 2014 and below the 89.2 forecast. August Job Openings slipped to 7.079 million, below forecasts and the lowest since March. New York Fed President John Williams said there is no need for urgency after the central bank's September meeting, and odds of an October rate hike fell to roughly a coin flip.


_11_18_2026_12_50_29_022597.jpg)



Please wait processing your request...